CD8A and cancer: This assumption is supported by the observation that across the 11,060 tumor samples in the The Cancer Genome Atlas Pan-Cancer (TCGA PANCAN) database (https://www.cancer.gov/tcga), CXCL9 expression predicts better CD8+ T-cell infiltration (figure 5E), and NRF2 profoundly suppresses this chemokine.